Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE D'AZE : revenue, balance sheet and financial ratios

PHARMACIE D'AZE is a French company founded 24 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in CHATEAU-GONTIER-SUR-MAYENNE (53200), this company of category PME shows in 2018 a revenue of 3.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Historique financier - PHARMACIE D'AZE (SIREN 440579233)
Kennzahl 2024 2023 2022 2021 2019 2018 2017 2016
Umsatz N/C N/C N/C N/C N/C 3 588 724 € N/C N/C
Nettoergebnis 217 087 € 272 313 € 236 310 € 308 417 € 277 978 € 281 033 € 197 135 € 209 720 €
EBITDA N/C N/C N/C N/C N/C 392 356 € N/C N/C
Nettomarge N/C N/C N/C N/C N/C 7.8% N/C N/C

Umsatz und Gewinn- und Verlustrechnung

In 2024, PHARMACIE D'AZE generates positive net income of 217 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 210 k€ -> 217 k€.

Nettoergebnis (2024) ?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Formel
Ordentliches Ergebnis + Außerordentliches Ergebnis - Ertragsteuern

217 087 €

Chargement du compte de résultat...

Évolution graphique

Anzeigen :

Aktiva

Chargement des données...

Passiva

Chargement des données...

Solvenz- und Verschuldungskennzahlen

The debt ratio (= Financial debt / Equity x 100) stands at 17%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 70%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Verschuldungsgrad (2024) ?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible
50-100% : Moderat
> 100% : Hoch

16.694%

Finanzielle Autonomie (2024) ?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Formel
(Eigenkapital / Bilanzsumme) x 100
Interpretation
> 30% : Gute Autonomie
20-30% : Durchschnitt
< 20% : Faible

70.408%

Anlagenaltersquote (2024) ?
Anlagenaltersquote
Definition
Misst den Abnutzungsgrad des Sachanlagevermögens.
Formel
Kumulierte Abschreibungen / Bruttoanlagevermögen x 100
Interpretation
< 50% : Neue Anlagen
50-70% : Normale Abnutzung
> 70% : Alternde Anlagen

53.6%

Entwicklung der Solvenzkennzahlen
PHARMACIE D'AZE

Positionnement sectoriel

Debt ratio
16.69 2024
2022
2023
2024
Q1: 16.46
Méd: 58.47
Q3: 154.89
Good

In 2024, the debt ratio of PHARMACIE D'AZE (16.69) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
70.41% 2024
2022
2023
2024
Q1: 28.91%
Méd: 49.95%
Q3: 69.47%
Excellent

In 2024, the financial autonomy of PHARMACIE D'AZE (70.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquiditätskennzahlen

The liquidity ratio (= Current assets / Current liabilities) stands at 193.31. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquiditätsquote (2024) ?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut
1-1.5 : Angemessen
< 1 : Risque de liquidité

193.307

Entwicklung der Liquiditätskennzahlen
PHARMACIE D'AZE

Positionnement sectoriel

Liquidity ratio
193.31 2024
2022
2023
2024
Q1: 129.47
Méd: 182.13
Q3: 260.78
Good

In 2024, the liquidity ratio of PHARMACIE D'AZE (193.31) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Umlaufvermögensbedarf und Zahlungsfristen

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operatives Working Capital (2024) ?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Formel
Stocks + Créances clients - Dettes fournisseurs
Interpretation
Negativ = freigesetzte Liquidität
Positiv = Finanzierungsbedarf

0 €

Kundenforderungen (2024) ?
Kundenforderungen (Tage)
Definition
Durchschnittliche Zahlungsfrist für Kunden.
Formel
(Kundenforderungen / Umsatz inkl. MwSt.) x 360
Interpretation
< 45j : Gut
45-60j : Durchschnitt
> 60j : Lang

0 j

Lieferantenverbindlichkeiten (2024) ?
Lieferantenverbindlichkeiten (Tage)
Definition
Durchschnittliche Zahlungsfrist von Lieferanten.
Formel
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität

0 j

Lagerumschlag (2024) ?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag

0 j

Entwicklung des Working Capital und der Zahlungsfristen
PHARMACIE D'AZE

Positionnement de PHARMACIE D'AZE dans son secteur

Vergleich mit der Branche Commerce de détail de produits pharmaceutiques en magasin spécialisé

Bewertungsschätzung

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE D'AZE is estimated at 3 030 695 € (range 2 110 528€ - 4 534 093€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
2110k€ 3030k€ 4534k€
3 030 695 € Range: 2 110 528€ - 4 534 093€
NAF 5 année 2024

Valuation method used

Net Income Multiple
217 087 € × 14.0x = 3 030 695 €
Range: 2 110 528€ - 4 534 093€

Only this financial indicator is available for this company.

Bewertungsentwicklung

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE D'AZE with other companies in the same sector:

Frequently asked questions about PHARMACIE D'AZE

What is the revenue of PHARMACIE D'AZE ?

The revenue of PHARMACIE D'AZE in 2018 is 3.6 M€.

Is PHARMACIE D'AZE profitable?

Yes, PHARMACIE D'AZE generated a net profit of 217 k€ in 2024.

Where is the headquarters of PHARMACIE D'AZE ?

The headquarters of PHARMACIE D'AZE is located in CHATEAU-GONTIER-SUR-MAYENNE (53200), in the department Mayenne.

Where to find the tax return of PHARMACIE D'AZE ?

The tax return of PHARMACIE D'AZE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE D'AZE operate?

PHARMACIE D'AZE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.